Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial

RCT (n=443) reports at least 30% improvement of abdominal pain and adequate relief of overall IBS symptoms in a greater number of B bifidum patients; 74 (34%) of 221 patients vs. 43 (19%) of 222 in placebo group (risk ratio 1.7, 95% CI 1.3–2.4; p=0.0007).

Lancet Gastroenterology and Hepatology